Relevance of sympathetic overactivity in hypertension and heart failure Therapeutic Implications

Size: px
Start display at page:

Download "Relevance of sympathetic overactivity in hypertension and heart failure Therapeutic Implications"

Transcription

1 Relevance of sympathetic overactivity in hypertension and heart failure Therapeutic Implications Uta C. Hoppe, MD, FESC Dep. of Internal Medicine II Paracelsus University Salzburg Austria

2 Disclosures Within the past 12 months, I have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company 1. Honoraria for lectures Astra, Bayer, Berlin Chemie, CVRx, Medtronic, Sanofi Aventis, Servier 2. Honoraria for advisory board activities Medtronic, Servier 3. Participation in clinical trials Ardian, Bosten Scientific, Boston, Braun, Cardiac Dimension, CVRx, Medtronic, Novartis, Remon, Sanofi- Aventis, Servier, Vessix Vascular 4. Research funding DFG, BMBF, ZMMK, Köln Fortune, Cardiac Dimension

3 Medical therapy in systolic heart failure Key role of sympathetic and neurohumoral blockade possibly Digitalis Aldosterone antagonist Diuretics Beta-Blockers ACE inhibitors or Angiotensine receptor blockers NYHA I NYHA II NYHA III NYHA IV ESC guidelines 212

4 Pentagram of antihypertensive drug combinations Diuretics Betablocker * Calcium channel blocker AT 1 -Antagonist ACE-Inhibitor Combination synergistic Combination possible * Combination for Dihydropyridine only Leitlinien zur Diagnostik und Behandlung der arteriellen Hypertonie 29; Dt. Hochdruckliga e.v. DHL - Deutsche Hypertonie Gesellschaft

5 Therapy-refractory arterial Hypertension - No achievement of target BP values - Exclusion of secundary hypertension - Adequate live stile modification - 3 antihypertensive drugs (including diuretics) - Approximately 8% of all hypertensive patients

6 Renal Denervation by catheter ablation

7 Reduction of systemic sympathetic Activity MSNA of patient with resistant Hypertension Baseline 1 M FU 12 M FU ECG 2 BP /17 mmhg 141/9 mmhg 127/81 mmhg MSNA 1 sec 56 bursts/min 41 bursts/min 19 bursts/min Improvement in cardiac baroreflex sensitivity after renal denervation (from 7.8 to 11.7msec/mmHg). Schlaich et al. NEJM 29;361:932

8 NA Spillover (ng/min) Effect of renal Denervation on renal and total Noradrenalin spillover NA Spillover (ng/min) Total renal NA spillover Total body NA spillover Mean office BP 161/17 141/9 Baseline - 47% p=.23 3 d post bilat. Denervation Left kidney Right kidney Baseline -28% p=.43 3 d post bilat. Denervation Schlaich et al. NEJM 29;361:932

9 Change of office BP after 6 months (mmhg) Renal Denervation by catheter ablation n=16; SBP 16 mmhg, 3 antihypertensive drugs, egfr of 45 ml/min/1.73m 2 Change of Office Blood Pressure after 6 months P< Systolic BP Renal Denervation Control Diastolic PB Esler et al. Lancet 21;376:193

10 Renal Denervation: Office Blood Pressure Change Maintained Blood Pressure Reduction over Time BP change (mmhg) Krum et al., ACC 212; Krum et al., Lancet 29;373;1275

11 Change from baseline to 3 months (mmhg) Cardiorespiratory Response to Exercise after RD Change of Blood Pressure at rest, maximum work rate and recovery RD (n=37) Control (n=9) SBP at rest DBP at rest SBP at peak work DBP at peak work SBP at recovery DBP at recovery Increase in max. work rate by 5 ± 13 W after RD Ukena et al. JACC 211;58:

12 Cardiorespiratory Response to Exercise after RD % of maximum work rate Ukena et al. JACC 211;58:

13 Change from baseline to 3 months (bpm) Change of heart rate (bpm) Cardiorespiratory Response to Exercise after RD Change of Heart rate at rest, maximum work rate and recovery Chronotropic reserve after RD Baseline 3 months after RD RD (n=37) Control (n=9) HR at rest Peak HR HR recovery 91% of pts. on beta-blockers % of maximum work rate Ukena et al. JACC 211;58:

14 Sympathetic Overactivity in arterial Hypertension and Heart Failure Baroreflex Hypertrophy Heart Failure Vasoconstriction Renin Na + /Volumen GFR

15 Baroreflex Activation Baroreflex- Stimul.-Sonden Implantierbarer Pulsgenerator

16 DEBuT 4-year Blood Pressure Reduction

17 Baseline BP or HR (mmhg or bpm) Change in BP or HR (mmhg or bpm) Barostim neo Trial Baseline BP or HR 3-month change of BP or HR by Baroreflex Activation SBP DBP HR SBP DBP HR History of RD (n=6) No History of RD (n=24) Hoppe et al. J Am Soc Hypertens. 212;6:27-6

18 Cardiovasc. Events (per 1 pts. years) Total Mortality (per 1 pts. years) Left ventricular mass - Prognosis Cardiovascular Events Total Mortality LV Mass-Index (Quintile) LV Mass-Index (Quintile) n=1925 Follow-up 4 years Schillaci et al, Hypertension 2

19 Effect of BP Reduction on LV Hypertrophy Dependence on treatment [%] -2-4 Meta-Analysis AT1 Receptor- Antagonist CA-Antagonist ACE-Inhibitor Diuretic Beta-Blocker Klingbeil et al. Am J Med 23; 115: 41-46

20 LVMI (g/m 2.7 ) IVSTd (mm) Regression of LV Hypertrophy after RD Resistant Hypertension; on average 4.7 antihypert. drugs: 46 pts. bilateral RD vs.18 pts. control LV mass index Interventricular septum thickness 8 7 p=.1 p<.1 p=.64 p=.81 p= p=.5 p= p=.855 p=.337 p= % Baseline 1 Month 6 Months RD Baseline 1 Month 6 Months Control Brandt et al. JACC 212;59:91-99

21 LVMI-Reduction (Δg/m 2.7 ) Regression of LV Hypertrophy after RD Resistant Hypertension; on average 4.7 antihypert. drugs: 46 pts. bilateral RD vs.18 pts. control Reduction of LV mass index 5 1 Month 6 Months -5-1 LVH no LVH -15 p=.8-2 p=.9 Brandt et al. JACC 212;59:91-99

22 LV Mass Index (g/m 2 ) Regression of LVH by Baroreflex Activation Reduction of LV Mass Index p-value < N = 6 Baseline N = 6 12 Months Bisognano et al. JACC 2112;57:1787

23 Mortality % Diastolic Dysfunction - Prognosis 25 - Total Mortality P<.1 moderate/severe diast. dysfunction mild dysfunction 5 - normal Years Schillaci et al, Hypertension 2

24 Mitral valve lateral E/E' Mitral valve lateral E/E' reduction Renal Denervation improves Diastolic Dysfunction Resistant Hypertension; on average 4.7 antihypert. drugs: 46 pts. bilateral RD vs.18 pts. control Intracardiac diastolic pressure 16 p<.1 p= Month 6 Months 14 p=.329 p<.1 p< Baseline 1 Month 6 Months -6 p<.1 p=.13 RD Control Baseline lat. E/É < Median Baseline lat. E/É > Median Brandt et al. JACC 212;59:91-99

25 Mitral valve lateral E/E' Renal Denervation improves Cardiac Function Resistant Hypertension; on average 4.7 antihypert. drugs: 46 pts. bilateral RD vs.18 pts. control Intracardiac diastolic pressure Systolic function p<.1 p=.6 p=.329 p<.1 p<.1 LVEDV 32.8±15.6 ml 25.6± months after RD; p= Baseline 1 Month 6 Months RD Control LV-EF 63.1±8.1 % 7.1± months after RD; p=.1 Brandt et al. JACC 212;59:91-99

26 Regression of LV Hypertrophy and Improvement of Cardiac Function after RD Potential Mechanisms - Blood pressure reduction per se - Direct sympatholytic effects on cardiomyocytes and fibrosis - Indirect effects on cardiomyocytes and cardiac matrix via metabolic modulation

27 Percentage of individuals Prevalence of Insulin Resistance in Hypertension Insulin sensitive intermediate resistant 39% 34% 47% 52% Untreated hypertension (n=56) Treated hypertension (n=7) 14% 14% < >18 Steady-state plasma glucose (SSPG, mg/dl) during the insulin suppression test Lima et al. Am J Hypertens 29;22:16

28 Change in fasting glucose (mg/dl) Change in fasting C-peptide (ng/ml) Change in fasting glucose (mg/dl) Change in fasting C-peptide (ng/ml) Effect of renal Denervation on Glucose Metabolism Change in fasting insulin (µiu/ml) Change in HOMA-IR (ng/ml) Change in fasting insulin (µiu/ml) Change in HOMA-IR (ng/ml) A A Change in fasting glucose (mg/dl) A A Change in fasting glucose (mg/dl) 1 month 1 month 3 months 3 months month 1 month 3 months 3 months Fasting glucose B 17.5 p=.589 p= p= p=.589 p=.177 p= p=.177 p= Renal denervation Renal denervation (n=35) (n=35) -1 p=.7 Renal Control denervation (n=15) (n=35) p=.7 Renal Control denervation (n=15) (n=35) -1 p= p=.7 p=.4 p=.4 Control (n=15) Control (n=15) -15 p= p=.4-15 B Change in fasting insulin (µiu/ml) B B Change in fasting insulin (µiu/ml) 1 month 1 month 3 months 3 months 1 monthp= monthp= months 3 months 15 p=.343 p= p=.927 p= p= p= p=.42 p= Insulin Renal denervation Renal denervation (n=35) (n=35) Renal Control denervation (n=15) (n=35) p=.42 Renal Control denervation (n=15) (n=35) p=.3 p=.3 p=.42 Control (n=15) Control (n=15) p=.3 p=.3 C C Change in fasting C-peptide (ng/ml) C C Change in fasting C-peptide (ng/ml) 1 month 1 month 3 months 3 months 1 monthp= monthp= months 3 months D 2. p=.356 C-Peptide p=.356 D p=.815 p= p= p= Renal denervation (n=35) Renal denervation (n=35) -2.5 Renal Control denervation (n=15) Renal denervation (n=35) (n=35) -2 Control (n=15) Control (n=15) Control (n=15) p= p=.22 p=.5 p= p=.22 p=.22 p=.5 p= Change in HOMA-IR (ng/ml) D D Change in HOMA-IR (ng/ml) Insulin sensitivity index 1 month 1 month 3 months 3 months 5 1 month 1 month 3 months 3 months 5 p=.246 p= p=.246 p= p=.962 p= p= p= Renal denervation Renal denervation (n=35) (n=35) Renal Control denervation (n=15) (n=35) -3 Renal Control denervation (n=15) (n=35) -4 Control (n=15) p=.23-4 p=.1 Control (n=15) p=.23 p=.1 p=.23-5 p=.23 p=.1 p=.1-5 Mahfoud et al. Circulation 211;123:194

29 Patients (%) Effect of RD on Glucose Metabolism Renal denervation (n=37) Control group (n=13) % 54% 32% n=3 n=4 6% 51% 43% 23% 46% 31% n=2 n=1 38% 38% 24% Diabetes IGT, IFG, or both NGT Baseline 3 months Baseline 3 months Mahfoud et al. Circulation 211;123:194

30 Total mortality % ASCOT-BPLA - study pts., atenolol±thiazide-based vs. amlodipine±perindopril-based therapy p =.247 Total Mortality Atenolol Thiazide (82 Events) Amlodipine Perindopril (738 Events) Years Terminated prematurely Dahlöf et al., Lancet 25; 366:

31 Effect of Central Hemodynamics on Outcome Risk for 1 mmhg increase of central Pulse Pressure and cardiov. Events Risk for 1% increase of central Alx and total Mortality Vlachopoulos et al., Eur Heart J 21;31:1865

32 Pressure (mmhg) Pressure (mmhg) Conduit Artery Function Evaluation (CAFE) study 2199 pts., atenolol±thiazide-based vs. amlodipine±perindopril-based therapy Peripheral pulse waveforms Central aortic waveforms Time (sec) Time (sec) equivalent brachial blood pressure reduction Williams et al. Circulation 26;113:1213

33 Conduit Artery Function Evaluation (CAFE) study 2199 pts., atenolol±thiazide-based vs. amlodipine±perindopril-based therapy Effect of therapy on Systolic BP: peripheral vs. central Williams et al. Circulation 26;113:1213

34 Conduit Artery Function Evaluation (CAFE) study 2199 pts., atenolol±thiazide-based vs. amlodipine±perindopril-based therapy Effect of therapy on Pulse Pressure: peripheral vs. central Williams et al. Circulation 26;113:1213

35 Peripheral BP (mmhg) Central aortic BP (mmhg) Effect of RD on peripheral & central aortic waveforms Peripheral pulse waveforms Central aortic waveforms Baseline 1 Month AP Baseline 1 Month AP Time (ms) Time (ms) Applanation tonometry (SphygmoCor) Brandt et al. JACC 212 in press

36 Central systolic BP (mmhg) Central PP (mmhg) Effect of RD on central blood pressure Resistant Hypertension; on average 4.8 antihypert. drugs: 11 pts. bilateral RD vs.1 pts. control Central systolic blood pressure Central Pulse Pressure p=.773 p<.1 p<.1 p=.14 p<.1 p<.1 p< p=.753 p<.1 p<.1 p=.24 p<.1 p<.1 p< Baseline 1 Month 3 Months 6 Months Baseline 1 Month 3 Months 6 Months RD, n=11 Control, n=1 Brandt et al. JACC 212 in press

37 Augmentation pressure (mmhg) Augmentation (%) Effect of RD on Augmentation Pressure Resistant Hypertension; on average 4.8 antihypert. drugs: 11 pts. bilateral RD vs.1 pts. control Augmentation Pressure Augmentation Index p<.1 p=.1 p=.3 p=.287 p=.3 p<.1 p< p<.1 p<.1 p=.56 p=.41 p=.47 p=.24 p= Baseline 1 Month 3 Months 6 Months Baseline 1 Month 3 Months 6 Months RD, n=11 Control, n=1 Brandt et al. JACC 212 in press

38 PWV reduction (m/s) Effect of RD on Arterial Stiffness Resistant Hypertension; on average 4.8 antihypert. drugs: 11 pts. bilateral RD vs.1 pts. control Pulse wave velocity Total RD group PWV cf > 9.6 m/s PWV cf > reference -1-2 p= p=.2 p=.1 p=.1 p<.1 p< Month 3 Months 6 Months p=.2 p=.2 p=.4 Brandt et al. JACC 212 in press

39 Relevance of sympathetic overactivity - Beta-blockade is an established treatment in heart failure and hypertension - Renal denervation (RD) or Baroreflex activation significantly reduce peripheral BP and LV-Hypertrophy - RD has the potential to improve diastolic and systolic function - RD has benefical effects on glucose metabolism - RD improves central hemodynamics (seems to be distinct vs. Beta-blockers) - Mortality studies are warrented Therapeutic Implications

40 Relevance of sympathetic overactivity in hypertension and heart failure Therapeutic Implications Uta C. Hoppe, MD, FESC Dep. of Internal Medicine II Paracelsus University Salzburg Austria

41 Renale Denervierung Hypertonus und andere Indikationen Uta C. Hoppe Dep. of Internal Medicine II Paracelsus University Salzburg Austria

Central Pressures and Prehypertension

Central Pressures and Prehypertension Central Pressures and Prehypertension Charalambos Vlachopoulos Associate Professor of Cardiology 1 st Cardiology Dept Athens Medical School Central Pressures and Prehypertension Charalambos Vlachopoulos

More information

What We've Learned from Simplicity HTN-1,2, and Registries

What We've Learned from Simplicity HTN-1,2, and Registries ANGIOPLASTY SUMMIT-TCTAP 2012 Seoul, Korea, April 24-27, 2012 What We've Learned from Simplicity HTN-1,2, and Registries Horst Sievert, Ann-Kathrin Ziegler, Benjamin Kaltenbach, Ilona Hofmann, Undine Pittl

More information

noradrenaline spillover and systemic blood pressure in patients with resistant hypertension

noradrenaline spillover and systemic blood pressure in patients with resistant hypertension Effects of renal sympathetic denervation on noradrenaline spillover and systemic blood pressure in patients with resistant hypertension Markus Schlaich Neurovascular Hypertension & Kidney Disease Laboratory

More information

CATHETER-BASED RENAL DENERVATION INCREASES INSULIN SENSITIVITY AND IMPROVES GLUCOSE METABOLISM IN PATIENTS WITH RESISTANT HYPERTENSION

CATHETER-BASED RENAL DENERVATION INCREASES INSULIN SENSITIVITY AND IMPROVES GLUCOSE METABOLISM IN PATIENTS WITH RESISTANT HYPERTENSION CATHETER-BASED RENAL DENERVATION INCREASES INSULIN SENSITIVITY AND IMPROVES GLUCOSE METABOLISM IN PATIENTS WITH RESISTANT HYPERTENSION F. Mahfoud, Ch. Ukena, B. Cremers, I. Kindermann, M. Kindermann, P.

More information

How clinically important are the results of the large trials in hypertension?

How clinically important are the results of the large trials in hypertension? How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université

More information

Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease

Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease Michelle P Kao, Donald S Ang, Steve Gandy, Chim C Lang, Allan D Struthers Division of

More information

Real World Experience with Renal Denervation Therapy

Real World Experience with Renal Denervation Therapy JCR 2013 Real World Experience with Renal Denervation Therapy Seung-Hyuk Choi Division of Cardiology Samsung Medical Center Seoul, Korea Hypertension A Major Public Health Burden Astonishing prevalence

More information

Evidence of Baroreflex Activation Therapy s Mechanism of Action

Evidence of Baroreflex Activation Therapy s Mechanism of Action Evidence of Baroreflex Activation Therapy s Mechanism of Action Edoardo Gronda, MD, FESC Heart Failure Research Center IRCCS MultiMedica Cardiovascular Department Sesto S. Giovanni (Milano) Italy Agenda

More information

Effects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France

Effects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France Effects of Renin-Angiotensin System blockade on arterial stiffness and function Gérard M. LONDON Manhès Hospital Paris, France Determinants of vascular overload (afterload) on the heart Peripheral Resistance

More information

When should you treat blood pressure in the young?

When should you treat blood pressure in the young? ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department

More information

Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly. Piotr Jankowski

Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly. Piotr Jankowski Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly Piotr Jankowski I Department of Cardiology and Hypertension CM UJ, Kraków, Poland piotrjankowski@interia.pl Vienna,

More information

The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension

The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension Michael Böhm, MD on behalf of the GSR Investigators March 30,

More information

Catheter Based Denervation for Heart Failure

Catheter Based Denervation for Heart Failure Catheter Based Denervation for Heart Failure David E. Kandzari, MD, FACC, FSCAI Chief Scientific Officer Director, Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia david.kandzari@piedmont.org

More information

Catheter-Based Renal Denervation Reduces Total Body and Renal Noradrenaline Spillover and Blood Pressure in Resistant Hypertension

Catheter-Based Renal Denervation Reduces Total Body and Renal Noradrenaline Spillover and Blood Pressure in Resistant Hypertension Catheter-Based Renal Denervation Reduces Total Body and Renal Noradrenaline Spillover and Blood Pressure in Resistant Hypertension Murray Esler, Markus Schlaich, Paul Sobotka, Rob Whitbourn, Jerzy Sadowski,

More information

OLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich,

OLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich, The effect of renal denervation in patients with advanced heart failure: OLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich, 27.08.2012 Disclosures MT: honoraria Bayer,

More information

Update on renal denervation: Latest data

Update on renal denervation: Latest data LINC 2018 Update on renal denervation: Latest data Felix Mahfoud Saarland University Hospital, Germany Potential Conflicts of Interest I have the following potential conflicts of interest to report: Research

More information

Renal Artery Denervation New Concepts in Hypertension Treatment

Renal Artery Denervation New Concepts in Hypertension Treatment Renal Artery Denervation New Concepts in Hypertension Treatment Istanbul Course of Interventional Cardiology J. Weil Medizinische Klinik II Kardiologie, Angiologie und internistische Intensivmedizin Universitätsklinikum,

More information

Transcatheter Renal Denervation and Hong Kong Experience

Transcatheter Renal Denervation and Hong Kong Experience Transcatheter Renal Denervation and Hong Kong Experience Dr. Steven Li Siu-lung FACC, FESC, FRCP, FACP Director, Heart Centre, Union Hospital President, Hong Kong Society of Congenital and Structural Heart

More information

Catheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension

Catheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension Catheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension Henry Krum, Markus Schlaich, Paul Sobotka, Rob Whitbourn, Jerzy Sadowski, Krzysztof Bartus, Boguslaw Kapelak, Horst

More information

Disclosure of Relationships

Disclosure of Relationships Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier

More information

Should beta blockers remain first-line drugs for hypertension?

Should beta blockers remain first-line drugs for hypertension? 1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,

More information

Aldosterone Antagonism in Heart Failure: Now for all Patients?

Aldosterone Antagonism in Heart Failure: Now for all Patients? Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C

More information

Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo?

Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Prof. Massimo Salvetti Clinica Medica University of Brescia Percieved risk Actual risk Sehestedt et al,

More information

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston

More information

Special Lecture 11/08/2013. Hypertension Dr. HN Mayrovitz

Special Lecture 11/08/2013. Hypertension Dr. HN Mayrovitz Special Lecture 11/08/2013 Hypertension Dr. HN Mayrovitz Arterial Blood Pressure (ABP) Major Factors Summarized Sympathetic Hormones Arteriole MAP ~ Q x TPR + f (V / C) SV x HR Renal SBP Hypertension =

More information

Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension

Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension Mathias C. Brandt, Felix Mahfoud, Sara Reda, Stephan H. Schirmer,

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

Causes of death in Diabetes

Causes of death in Diabetes Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase

More information

Renal Sympathetic Denervation for Treatment of Resistant Hypertension: 18-Month Results from the Symplicity HTN-2 Randomized Controlled Trial

Renal Sympathetic Denervation for Treatment of Resistant Hypertension: 18-Month Results from the Symplicity HTN-2 Randomized Controlled Trial Renal Sympathetic Denervation for Treatment of Resistant Hypertension: 18-Month Results from the Symplicity HTN-2 Randomized Controlled Trial Prof Murray Esler Baker IDI Heart and Diabetes Institute, Melbourne

More information

Therapeutic Targets and Interventions

Therapeutic Targets and Interventions Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium

More information

Update in Hypertension

Update in Hypertension Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded

More information

Baroreflex Activation Therapy: Integrated Autonomic Neuromodulation for Heart Failure and Hypertension

Baroreflex Activation Therapy: Integrated Autonomic Neuromodulation for Heart Failure and Hypertension Baroreflex Activation Therapy: Integrated Autonomic Neuromodulation for Heart Failure and Hypertension Robert S. Kieval, VMD, PhD Founder & Chief Technology Officer, CVRx, Inc. Financial Disclosure I,

More information

CIC-P Nancy. Disclosures

CIC-P Nancy. Disclosures Pr Patrick Rossignol Inserm 1433 Clinical Investigation Center Hypertension and Heart Failure Unit Association Lorraine pour le Traitement de l Insuffisance Rénale (ALTIR) CHRU, Lorraine University Nancy,

More information

HTA ET DIALYSE DR ALAIN GUERIN

HTA ET DIALYSE DR ALAIN GUERIN HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age

More information

Renal Denervation. Henry Krum MBBS PhD FRACP. Centre of Cardiovascular Research & Monash University/Alfred Hospital;

Renal Denervation. Henry Krum MBBS PhD FRACP. Centre of Cardiovascular Research & Monash University/Alfred Hospital; Renal Denervation Henry Krum MBBS PhD FRACP Centre of Cardiovascular Research & Education in Therapeutics, Monash University/Alfred Hospital; Alfred Heart Centre, The Alfred Hospital, Melbourne Australia

More information

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection

More information

Special Lecture 10/28/2012

Special Lecture 10/28/2012 Special Lecture 10/28/2012 HYPERTENSION Dr. HN Mayrovitz Special Lecture 10/28/2012 Arterial Blood Pressure (ABP) - Definitions ABP Review Indirect Oscillographic Method Resistance (R), Compliance (C)

More information

Catheter-Based Renal Denervation (RDN)

Catheter-Based Renal Denervation (RDN) Hypertension lecture 3: Catheter-Based Renal Denervation (RDN) Adapted from slides prepared by Dr IOEBRAHIM, UNITAS HOSPITAL and others Hypertension Epidemiology 30% Untreated 35% Treated & Controlled

More information

Measurement of Arterial Stiffness: Why should I measure both PWA and PWV?

Measurement of Arterial Stiffness: Why should I measure both PWA and PWV? Measurement of Arterial Stiffness: Why should I measure both PWA and PWV? Central blood pressure and measures of arterial stiffness have been shown to be powerful predictors of major cardiovascular events,

More information

Radiofrequency Energy Provides Safe & Durable Blood Pressure Reduction: Complete 3 Year Results from Symplicity HTN-1

Radiofrequency Energy Provides Safe & Durable Blood Pressure Reduction: Complete 3 Year Results from Symplicity HTN-1 Radiofrequency Energy Provides Safe & Durable Blood Pressure Reduction: Complete 3 Year Results from Symplicity HTN-1 Henry Krum MBBS PhD FRACP FESC for the Symplicity I Investigators CCRE Therapeutics,

More information

Devices and Long-Term Outcomes of Renal Denervation for Hypertension

Devices and Long-Term Outcomes of Renal Denervation for Hypertension 18th ANGIOPLASTY SUMMIT-TCTAP 2013 Seoul, Korea, April 23-26, 2013 Devices and Long-Term Outcomes of Renal Denervation for Hypertension Horst Sievert, Ilona Hofmann, Laura Vaskelyte, Stefan Bertog, Simon

More information

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with

More information

The Hearth Rate modulators. How to optimise treatment

The Hearth Rate modulators. How to optimise treatment The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,

More information

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals

More information

Hypertension and diabetic nephropathy

Hypertension and diabetic nephropathy Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney

More information

Cardiovascular Diseases in CKD

Cardiovascular Diseases in CKD 1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9

More information

Renal denervation: Current evidence and remaining uncertainties

Renal denervation: Current evidence and remaining uncertainties Renal denervation: Current evidence and remaining uncertainties Michel Azizi Georges Pompidou European Hospital Hypertension Unit ESH excellence Center Paris Descartes University Clinical Investigation

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

OLOMOUC I Registry. The effect of renal denervation in patients with advanced heart failure:

OLOMOUC I Registry. The effect of renal denervation in patients with advanced heart failure: The effect of renal denervation in patients with advanced heart failure: OLOMOUC I Registry M. Táborský, M. Lazárová, J. Václavík, D. Richter, D. Vindiš, M. Kamasová, A. Louis, J. Jarkovský * I.IKK FNOL,

More information

Slide notes: References:

Slide notes: References: 1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory

More information

Renal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School

Renal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School Renal Denervation by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School Disclosure Information ACOI Annual Meeting I have the following financial relationships to disclose:

More information

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk

More information

THE HEART AND HYPERTENSION. Philippe Gosse Hypertension Unit University Hospital Bordeaux

THE HEART AND HYPERTENSION. Philippe Gosse Hypertension Unit University Hospital Bordeaux THE HEART AND HYPERTENSION Philippe Gosse Hypertension Unit University Hospital Bordeaux INCREASED LVM Cardiomyocytes hypertrophy is a response to pressure overload This response is influenced by many

More information

Is there a mechanism of interaction between hypertension and dyslipidaemia?

Is there a mechanism of interaction between hypertension and dyslipidaemia? Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational

More information

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Association between arterial stiffness and cardiovascular risk factors in a pediatric population + Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro

More information

Clinical application of Arterial stiffness. pulse wave analysis pulse wave velocity

Clinical application of Arterial stiffness. pulse wave analysis pulse wave velocity Clinical application of Arterial stiffness pulse wave analysis pulse wave velocity Arterial system 1. Large arteries: elastic arteries Aorta, carotid, iliac, Buffering reserve: store blood during systole

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%

More information

Update on Current Trends in Hypertension Management

Update on Current Trends in Hypertension Management Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student

More information

Managing anti-hypertensive treatment with SphygmoCor XCEL

Managing anti-hypertensive treatment with SphygmoCor XCEL Managing anti-hypertensive treatment with SphygmoCor XCEL Measurement of Central aortic BP may provide valuable information on antihypertensive drug action that is not apparent with assessment of Brachial

More information

ACE inhibitors: still the gold standard?

ACE inhibitors: still the gold standard? ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University

More information

INTERNATIONAL REGISTRY FOR AMBULATORY BLOOD PRESSURE AND ARTERIAL STIFFNESS TELEMONITORING

INTERNATIONAL REGISTRY FOR AMBULATORY BLOOD PRESSURE AND ARTERIAL STIFFNESS TELEMONITORING INTERNATIONAL REGISTRY FOR AMBULATORY BLOOD PRESSURE AND ARTERIAL STIFFNESS TELEMONITORING VASOTENS Registry Vascular health ASsessment Of The hypertensive patients Project Coordinator: Dr. Stefano Omboni

More information

Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study

Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Dr. Antonio Magaña M.D. (on behalf I-PREFER investigators group) Stockholm, Sweden, August

More information

ACE inhibitors vs ARBs Myths and Facts

ACE inhibitors vs ARBs Myths and Facts ACE inhibitors vs ARBs Myths and Facts Prof. Dr. med. Frank Ruschitzka, FRCP (Edinburgh) Director Heart Failure/Transplantation Clinic University Clinic Zurich Switzerland Conflict of interest: Bayer,

More information

Hypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF

Hypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step

More information

How to assess the hemodynamic importance of a renal artery stenosis. Felix Mahfoud, MD Saarland University Hospital Homburg/Saar, Germany

How to assess the hemodynamic importance of a renal artery stenosis. Felix Mahfoud, MD Saarland University Hospital Homburg/Saar, Germany How to assess the hemodynamic importance of a renal artery stenosis Felix Mahfoud, MD Saarland University Hospital Homburg/Saar, Germany How to assess renal artery stenosis severity 1. Non-invasive assessments

More information

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine

More information

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis

More information

The role of physical activity in the prevention and management of hypertension and obesity

The role of physical activity in the prevention and management of hypertension and obesity The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity

More information

Hypertension Update 2009

Hypertension Update 2009 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin

More information

Departments of Cardiology and Vascular Surgery Michaelidion Cardiac Center University of Ioannina, Greece

Departments of Cardiology and Vascular Surgery Michaelidion Cardiac Center University of Ioannina, Greece Departments of Cardiology and Vascular Surgery Michaelidion Cardiac Center University of Ioannina, Greece ARGYRIS Vassilis, PEROULIS Michalis, MATSAGKAS Miltiadis, BECHLIOULIS Aris, MICHALIS Lampros, NAKA

More information

When blood pressure is measured conventionally over. Hypertension

When blood pressure is measured conventionally over. Hypertension Hypertension Differential Impact of Blood Pressure Lowering Drugs on Central Aortic Pressure and Clinical Outcomes Principal Results of the Conduit Artery Function Evaluation (CAFE) Study The CAFE Investigators,

More information

Blood Pressure Response Under Chronic Antihypertensive Drug Therapy

Blood Pressure Response Under Chronic Antihypertensive Drug Therapy Journal of the American College of Cardiology Vol. 53, No. 5, 29 29 by the American College of Cardiology Foundation ISSN 735-197/9/$36. Published by Elsevier Inc. doi:1.116/j.jacc.28.9.46 Hypertension

More information

Role of Sympathetic Nervous System in Hypertension

Role of Sympathetic Nervous System in Hypertension Role of Sympathetic Nervous System in Hypertension BP = CO x PVR SV HR DEFENSE REACTION Suppressed vagal activity Increased sympathetic activity to heart, veins, kidneys, splachnic region, skin Skeletal

More information

hypertension Head of prevention and control of CVD disease office Ministry of heath

hypertension Head of prevention and control of CVD disease office Ministry of heath hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension

More information

Definition of Congestive Heart Failure

Definition of Congestive Heart Failure Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million

More information

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function:

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography

More information

Combination of renin-angiotensinaldosterone. how to choose?

Combination of renin-angiotensinaldosterone. how to choose? Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants

More information

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016 Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34

More information

The Road to Renin System Optimization: Renin Inhibitor

The Road to Renin System Optimization: Renin Inhibitor The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension

More information

Coronary artery disease (CAD) risk factors

Coronary artery disease (CAD) risk factors Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes

More information

Hypertensive heart disease and failure

Hypertensive heart disease and failure Hypertensive heart disease and failure Prof. Dr. Alan Fraser Cardiff University The heart in hypertension Pathophysiology of LV adaptation Regional development of hypertrophy Stress testing - inducible

More information

Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy

Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy ORIGINAL ARTICLE 5 RAAS inhibitors should be avoided if possible in patients with obstructive HCM Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy Katrin Witzel,

More information

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function:

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography

More information

Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14

Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Disclosures Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance

More information

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs

More information

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef Review of Cardiac Imaging Modalities in the Renal Patient George Youssef ECHO Left ventricular hypertrophy (LVH) assessment Diastolic dysfunction Stress ECHO Cardiac CT angiography Echocardiography - positives

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,

More information

Diastolic Function. Rick Nishimura Leighton Professor of CV Diseases Mayo Clinic No Disclosures

Diastolic Function. Rick Nishimura Leighton Professor of CV Diseases Mayo Clinic No Disclosures Diastolic Function Rick Nishimura Leighton Professor of CV Diseases Mayo Clinic No Disclosures Heart = Pump Heart Failure Systolic Dysfunction Diastolic Dysfunction Diastole is a complex sequence of multiple

More information

Mechanisms of heart failure with normal EF Arterial stiffness and ventricular-arterial coupling. What is the pathophysiology at presentation?

Mechanisms of heart failure with normal EF Arterial stiffness and ventricular-arterial coupling. What is the pathophysiology at presentation? Mechanisms of heart failure with normal EF Arterial stiffness and ventricular-arterial coupling What is the pathophysiology at presentation? Ventricular-arterial coupling elastance Central arterial pressure

More information

Individual Study Table Referring to Part of Dossier: Volume: Page:

Individual Study Table Referring to Part of Dossier: Volume: Page: Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For

More information

Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial

Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial Kenji Ueshima 1, Shinji Yasuno 1, Sachiko Tanaka 1, Akira Fujimoto 1, Toshio Ogihara 2, Takao

More information

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

With an unrestricted educational grant from. The Interventional Treatment of Resistant Hypertension

With an unrestricted educational grant from. The Interventional Treatment of Resistant Hypertension With an unrestricted educational grant from The Interventional Treatment of Resistant Hypertension Felix Mahfoud Interventional Cardiology University Hospital Homburg/Saar Germany Dr. Mahfoud graduated

More information

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome G. Deswarte, AS. Polge, N. Lamblin, A. Millaire, M. Richardson, C. Bauters,

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information